In a range of neurodegenerative disease models, GM-CSF treatment is linked to improved locomotor function and cognitive function that correlate to altered innate and adaptive immune functions [21, 22, 24, 25, 73–75]. Here, CSF2 is linked to neurodegenerative disease.